open access

Vol 12, No 2 (2016)
Review paper
Published online: 2016-08-04
Get Citation

The impact of combined oral contraception and hormone replacement therapy on breast cancer development

Anna Niwińska
Oncol Clin Pract 2016;12(2):43-51.

open access

Vol 12, No 2 (2016)
REVIEW ARTICLES
Published online: 2016-08-04

Abstract

The assessment of breast cancer relative morbidity risk in women taking oral contraceptives (OC) or hormone replacement therapy (HRT) — currently known as menopausal hormone therapy — is still a challenge. The analysed groups of women vary widely depending on the type, route of application and doses of hormones, the duration of administration, and the time from therapy cessation. Moreover, the risk of breast cancer depends on the patient’s genetic predisposition, and for this reason the analyses of OC and HRT should be performed separately in the group of healthy women, in BRCA1/2 mutation carriers, and in breast cancer survivors. This paper was aimed to analyse the safety of OC and HRT in three groups of women depending on the risk of breast cancer development (healthy women) or breast cancer recurrence (breast cancer survivors).

Abstract

The assessment of breast cancer relative morbidity risk in women taking oral contraceptives (OC) or hormone replacement therapy (HRT) — currently known as menopausal hormone therapy — is still a challenge. The analysed groups of women vary widely depending on the type, route of application and doses of hormones, the duration of administration, and the time from therapy cessation. Moreover, the risk of breast cancer depends on the patient’s genetic predisposition, and for this reason the analyses of OC and HRT should be performed separately in the group of healthy women, in BRCA1/2 mutation carriers, and in breast cancer survivors. This paper was aimed to analyse the safety of OC and HRT in three groups of women depending on the risk of breast cancer development (healthy women) or breast cancer recurrence (breast cancer survivors).

Get Citation

Keywords

oral contraceptives, hormone replacement therapy, menopausal hormone therapy, breast cancer

About this article
Title

The impact of combined oral contraception and hormone replacement therapy on breast cancer development

Journal

Oncology in Clinical Practice

Issue

Vol 12, No 2 (2016)

Article type

Review paper

Pages

43-51

Published online

2016-08-04

Bibliographic record

Oncol Clin Pract 2016;12(2):43-51.

Keywords

oral contraceptives
hormone replacement therapy
menopausal hormone therapy
breast cancer

Authors

Anna Niwińska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl